<!doctype html>
<html lang="en">
   <head>
      <meta charset="utf-8"/>
      <meta name="viewport" content="width=device-width,initial-scale=1,user-scalable=no"/>
      <meta name="format-detection" content="telephone=no"/>
      <meta name="apple-mobile-web-app-capable" content="yes"/>
      <meta name="apple-mobile-web-app-status-bar-style" content="black"/>
      <title>
         <!-- Key Message Description -->
      </title>
      <link rel="stylesheet" href="../shared/shared-dificid-v4/js/ext/avModal/themes/default.css"/>
      <link rel="stylesheet" href="../shared/shared-dificid-v4/css/shared-main.css"/>
      <link rel="stylesheet" href="css/specific.css"/>
   </head>
   <body data-pix="true" data-SlideName="Results">
      <section id="wrapper">
         <!-- Landscape Header with Tracking -->
         <header class="landscapeHeader">
            <div class="homeIcon" data-slide="0.0_dificid_v4_home.zip">&nbsp;</div>
            <div class="halfMoon" id="halfMoonTOC">&nbsp;</div>
         </header>
         <section id="contentWrapper">
            <div id="content">
               <!--====== main content Starts ========--> 
               <!-- Navigation Starts-->
               <nav data-count="six">&nbsp;</nav>
               <!-- Navigation Ends --> 
               <!-- Landscape Start -->
               <div id="landscape">
                  <!-- Slide Specific Code Start -->
                  <section>
                     
                     <div class="bgWhiteBox">
                        <div class="upperborder">
                           <div class="overlay">
                              <h1 class=" darkGreen light fs29 conclusion">
                                 Results
                              </h1>
                           </div>
                           <div class="assumScrollbarContent content bottomScroll">
                              <h3 class="optimal darkGreen helveticaBold fs18">
                                 Optimal treatment strategy for CDI was number 44:
                              </h3>
                              <p class="result00 light fs16 darkGreen">
                                 Fidaxomicin for non-severe initial CDI
                              </p>
                              <div class="borderFour">
                                 &nbsp;
                              </div>
                              <p class="result01 light fs16 darkGreen">
                                 Vancomycin for severe CDI
                              </p>
                              <div class="borderFive">
                                 &nbsp;
                              </div>
                              <p class="result02 light fs16 darkGreen">
                                 Fidaxomicin for first recurrence
                              </p>
                              <div class="borderSix">
                                 &nbsp;
                              </div>
                              <p class="result03 light fs16 darkGreen">
                                 Fecal microbiota transplant (FMT) for subsequent recurrence
                              </p>
                              <ul class="results fs14 lh18">
                                 <li>
                                    This strategy had an ICER of $31,751 per QALY, which falls below the willingness-to-pay<br/> threshold of $100,000 per QALY gained     
                                 </li>
                                 <li class="effective">
                                    The least expensive, least beneficial strategy was the use of metronidazole for initial <br/>non-severe CDI and vancomycin for severe initial CDI and all recurrences of CDI
                                 </li>
                              </ul>
                              <h3 class="limitOne darkGreen helveticaBold fs18">
                                 Dominant CDI treatment strategies
                              </h3>
                              <div class="table">
                                 <div class="dominant">
                                    <p class="strategy fs12 condensedBold">Strategy ID Numbers</p>
                                    <p class="least fs10 lh14 helveticaRoman"><span class="number bold fs14 lh13">3</span><br/> Least<br/> expensive,<br/> least<br/> beneficial </p>
                                    <p class="one fs10"><span class="number bold fs14">1</span></p>
                                    <p class="twentyfive fs10"><span class="number bold fs14">25</span></p>
                                    <p class="most fs10 lh14 helveticaRoman"><span class="number bold fs14">37</span><br/> Second<br/> most<br/> effective</p>
                                    <p class="fourtythree fs10 lh14 helveticaRoman"><span class="number bold fs14">43</span><br/> Third most<br/> effective</p>
                                    <p class="fourtyfour fs10 lh14 helveticaRoman"><span class="number bold fs14">44</span><br/>Most<br/> effective</p>
                                 </div>
                                 <div class="dominant00">
                                    <p class="strategy00 fs12 condensedBold">Non-severe</p>
                                    <p class="least00 fs10 lh12 helveticaRoman">Metronidazole</p>
                                    <p class="one00 fs10 helveticaRoman">Vancomycin</p>
                                    <p class="twentyfive00 fs10 helveticaRoman">Vancomycin</p>
                                    <p class="most00 fs10 lh12 helveticaRoman">Vancomycin</p>
                                    <p class="fourtythree00 fs10 lh12 helveticaRoman">Vancomycin</p>
                                    <p class="fourtyfour00 fs10 lh12 bold">Fidaxomicin</p>
                                 </div>
                                 <div class="severe">
                                     <p class="severeZero fs12 condensedBold">Severe</p>
                                     <p class="severeOne fs10 lh12 helveticaRoman">Vancomycin</p>
                                     <p class="severeTwo fs10 helveticaRoman">Vancomycin</p>
                                     <p class="severeThree fs10 helveticaRoman">Vancomycin</p>
                                     <p class="severeFour fs10 lh12 helveticaRoman">Vancomycin</p>
                                     <p class="severeFive fs10 lh12 helveticaRoman">Vancomycin</p>
                                     <p class="severeSix fs10 lh12 bold">Vancomycin</p>
                                 </div>
                                 <div class="reccurence">
                                     <p class="reccurenceZero fs12 condensedBold">First reccurence</p>
                                     <p class="reccurenceOne fs10 lh12 helveticaRoman">Vancomycin</p>
                                     <p class="reccurenceTwo fs10 helveticaRoman">Vancomycin</p>
                                     <p class="reccurenceThree fs10 helveticaRoman">Vancomycin</p>
                                     <p class="reccurenceFour fs10 lh12 helveticaRoman">Vancomycin</p>
                                     <p class="reccurenceFive fs10 lh12 helveticaRoman">Fidaxomicin</p>
                                     <p class="reccurenceSix fs10 lh12 bold">Fidaxomicin</p>
                                 </div>
                                 <div class="plus">
                                     <p class="plusZero fs12 condensedBold">Second+ reccurence</p>
                                     <p class="plusOne fs10 lh12 helveticaRoman">Vancomycin</p>
                                     <p class="plusTwo fs10 helveticaRoman">Vancomycin</p>
                                     <p class="plusThree fs10 helveticaRoman">Vancomycin</p>
                                     <p class="plusThreeone fs10 helveticaRoman">and Rifaximin</p>
                                     <p class="plusFour fs10 lh12 helveticaRoman">FMT</p>
                                     <p class="plusFive fs10 lh12 helveticaRoman">FMT</p>
                                     <p class="plusSix fs10 lh12 bold">FMT</p>
                                </div>
                                <div class="cost">
                                    <p class="costZero fs12 condensedBold">Cost (USD)</p>
                                     <p class="costOne fs10 lh12 helveticaRoman">$64,509</p>
                                     <p class="costTwo fs10 helveticaRoman">$64,692</p>
                                     <p class="costThree fs10 helveticaRoman">$64,917</p>
                                     <p class="costFour fs10 lh12 helveticaRoman">$65,125</p>
                                     <p class="costFive fs10 lh12 helveticaRoman">$65,411</p>
                                     <p class="costSix fs10 lh12 helveticaRoman">$65,889</p>
                                </div>
                                <div class="effectiveness">
                                     <p class="effectivenessZero fs12 condensedBold">Effectiveness (QALYs)</p>
                                     <p class="effectivenessOne fs10 lh12 helveticaRoman">12.280</p>
                                     <p class="effectivenessTwo fs10 helveticaRoman">12.352</p>
                                     <p class="effectivenessThree fs10 helveticaRoman">12.406</p>
                                     <p class="effectivenessFour fs10 lh12 helveticaRoman">12.426</p>
                                     <p class="effectivenessFive fs10 lh12 helveticaRoman">12.442</p>
                                     <p class="effectivenessSix fs10 lh12 bold">12.451</p>
                                </div>
                                <div class="incremental">
                                    <p class="incrementalZero fs12 condensedBold">Incremental Effectiveness (QALYs)</p>
                                     <p class="incrementalOne fs10 lh12 helveticaRoman"></p>
                                     <p class="incrementalTwo fs10 helveticaRoman">0.072</p>
                                     <p class="incrementalThree fs10 helveticaRoman">0.054</p>
                                     <p class="incrementalFour fs10 lh12 helveticaRoman">0.020</p>
                                     <p class="incrementalFive fs10 lh12 helveticaRoman">0.016</p>
                                     <p class="incrementalSix fs10 lh12 bold">0.009</p>
                                </div>
                                <div class="icer">
                                    <p class="icerZero fs12 condensedBold">ICER ($/QALY)</p>
                                     <p class="icerOne fs10 lh12 helveticaRoman">----</p>
                                     <p class="icerTwo fs10 helveticaRoman">2,537</p>
                                     <p class="icerThree fs10 helveticaRoman">4,208</p>
                                     <p class="icerFour fs10 lh12 helveticaRoman">10,383</p>
                                     <p class="icerFive fs10 lh12 helveticaRoman">27,428</p>
                                     <p class="icerSix fs10 lh12 bold">31,751</p>
                                </div>
                              </div>
                              
                              <div class="methodButton fs14 lh19">
                                 <div class="methodButtonOne avModal bold fs14" data-href="#modalvalidation" data-top="54" data-left="48" data-width="928" data-height="582" data-overlayOpacity="0.5" data-swap="true" data-switch="false" data-onShowNav="false">
                                    <p class="methodBtnOneText">Model Validation</p>
                                 </div>
                                 <div class="methodButtonTwo avModal bold fs14" data-href="#sensitivity" data-top="52" data-left="48" data-width="928" data-height="583" data-overlayOpacity="0.5" data-swap="true" data-switch="false" data-onShowNav="false">
                                    <p class="methodBtnOneText">Sensitivity Analysis</p>
                                 </div>
                              </div>    
                           </div>
                        </div>
                     </div>
                  </section>
                  <div class="footerNote fs14 helveticaRoman">
                     Provided pursuant to FDAMA  &sect; <span class="footerNumber">114.</span> 
                  </div>
                  <!-- Slide Specific Code End -->
                  <!-- SmartBalance Headline Start -->
                  <div class="ssiTxt">
                     Important Safety Information
                  </div>
                  <!-- SmartBalance Headline End -->
                  <!-- SmartBalance Content starts -->
                  <section id="smartBalance">&nbsp;</section>
                  <!-- SmartBalance Content ends -->
               </div>
               <!-- Landscape End -->
            </div>
            <!--======== main content Ends ===========-->
         </section>
         <!--//contentWrapper-->
         <footer data-count="six">&nbsp;</footer>
      </section>
      <!--//wrapper-->
      <!-- ================= Global popups Start=====================-->
      <section id="globalComponent">&nbsp;</section>
      <section class="avModalContainer" id="modalvalidation">
                                 <div class="treatmentContainer">
                                    <div class="modelValid fs22 bold darkGreen">
                                       <p class="headOne">Model validation</p>
                                    </div>
                                    <ul class="limitations fs14 helveticaRoman lh18">
                                       <li>
                                          The study validated the simulation model by comparing the short-term, model-predicted mortality to that observed in large CDI<br/>patient cohorts    
                                       </li>
                                       <li class="effective">
                                          Our average 60-day mortality for all 48 strategies was 8%, whereas many studies report 30-day mortality of 9% to 10%     
                                       </li>
                                    </ul>
                                 </div>
                              </section>
                              <section class="avModalContainer" id="sensitivity">
                                 <div class="sensitivityContainer">
                                    <div class="analysis fs22 bold darkGreen">
                                       <p class="headTwo">Sensitivity analysis</p>
                                    </div>
                                    <p class="way fs14 helveticaRoman">In 1-way sensitivity analysis of fidaxomicin pricing, fidaxomicin remained the optimal treatment regimen for non-severe CDI up to a <br/>price of $5,100 (115% AWP) per 10-day course. </p>
                                    <ul class="sensitivityTwo fs14 helveticaRoman lh18">
                                       <li>
                                          Above this price, vancomycin was preferred for non-severe CDI
                                       </li>
                                       <li class="effective">
                                          Above a cost of $4,590 (104% of AWP) per 10-day course of fidaxomicin, vancomycin was also preferred for first recurrent CDI <br/> and fidaxomicin was not cost-effective for any severity or recurrence of CDI
                                       </li>
                                       <li>
                                          When varying FMT pricing, only at a cost greater than $14,806 (over 9 times the estimated base case cost) was FMT no longer<br/> cost-effective, with vancomycin + rifaximin preferred for treating second or subsequent CDI recurrence. In probabilistic sensitivity<br/> analysis, assuming a willingness-to-pay threshold of $100,000 per QALY gained, strategy 44 was optimal in 47% of simulations 
                                       </li>
                                       <span class="ullast">
                                       — &nbsp;As long as the willingness-to-pay threshold was above $30,000/QALY, this was the optimal strategy on average as well
                                       </span>
                                    </ul>
                                 </div>
                              </section>
      <!-- ================= Global popups End=====================-->
      <script src="../shared/shared-dificid-v4/js/jquery-2.2.3.min.js" charset="utf-8"></script>
      <script src="../shared/shared-dificid-v4/shared-main.js" charset="utf-8"></script>
   </body>
</html>